Intellia Therapeutics, Inc. (NTLA) | Investment Case

1. Company Snapshot

1.a. Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.

In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.Intellia Therapeutics, Inc.has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.

to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc.to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.The company was formerly known as AZRN, Inc.

Intellia Therapeutics, Inc.was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on NTLA

Intellia Therapeutics' recent momentum is driven by strong progress in its late-stage gene editing therapies. The company's lead candidate, lonvo-z, has completed Phase 3 enrollment for hereditary angioedema (HAE), offering a one-time infusion advantage over competitors. Recent earnings report showed a narrower Q2 loss and beat on revenues. Additionally, Cathie Wood's Ark Invest has taken a position in the stock, and Intellia's gene therapy pipeline progress has garnered growing investor attention. (Source: Zacks, Globe Newswire)

1.c. Company Highlights

Last Price	15.31
Change Percentage	0.66%
Open	15.45
Previous Close	15.21
Market Cap ( Millions)	1809
Volume	4304004
Year High	28.25
Year Low	6.83
M A 50	13.35
M A 200	13.06

FCF Yield	-21.89%
Dividend Yield	0.00%
ROE	-56.63%
Debt / Equity	13.90%
Net Debt / EBIDTA	14.88%
Price To Book	2.47
Price Earnings Ratio	-4.02
Price To FCF	-4.57
Price To sales	26.73
EV / EBITDA	-4.18

2. Intellia Therapeutics' Q4 2025 Earnings: A Deeper Dive into the Numbers and Pipeline Progress

Intellia Therapeutics reported a net loss of $95.8 million for the fourth quarter of 2025, with collaboration revenue coming in at $23 million. Research and development expenses were $88.7 million, and the company's cash balance stood at $605.1 million as of December 31, 2025. The actual EPS for the quarter was -$0.83, beating estimates of -$0.99. Analysts are expecting a significant revenue growth of 387.7% next year. The company's current valuation metrics show a P/S Ratio of 23.59 and an EV/EBITDA of -3.67, indicating a high growth expectation.

Publication Date: Mar -02

                                    📋 Highlights
                                    Cash Position:
                                                $605.1 million cash balance (Dec 31, 2025) expected to fund operations through mid-2027.
Lonvo-Z Market Potential:
                                                99% patient willingness to take and 92% HCP prescribing intent, with BLA submission planned for H2 2026 after HAELO trial enrollment (80 pts) in Sept 2025.
Financials:
                                                Q4 2025 net loss of $95.8 million, driven by $88.7M R&D expenses vs $23M collaboration revenue.
Nex-Z Clinical Hold:
                                                MAGNITUDE-2 enrollment paused due to liver issues; FDA lifted hold, with resumption expected by H2 2026.

                                

Pipeline Progress and Clinical Trials

The company made significant progress in its pipeline, completing enrollment in the HAELO phase 3 clinical trial for lonvo-z, with 80 patients, in September. The company expects to present top-line data by mid-2026 and plans to submit a Biologics License Application (BLA) in the second half of 2026. For nex-z, the company is working to resume patient screening in the MAGNITUDE-2 trial after the FDA lifted the clinical hold. As the company's CEO mentioned, "We believe that lonvo-z could deliver significant savings to patients and payers, and its commercial success could fundamentally change the future capital needs of the company."

Commercial Strategy and Market Potential

The company is building out its sales and reimbursement field teams, finalizing its distribution models, and identifying U.S. treatment centers in preparation for a potential launch of lonvo-z. Market research showed that 99% of patients would be likely to take lonvo-z if it were approved, and 92% of healthcare providers would prescribe it to their patients. The company expects to achieve mid-single-digit market share in the first year, which could fully fund its operations.

Regulatory Updates and Risk Mitigation

The company is working with the FDA to address concerns related to the MAGNITUDE-2 trial and the cardiomyopathy (CM) study. The company has introduced additional blood draws to monitor liver function and plans to implement a short course of steroids to address potential immunological issues. The FDA's decision to lift the hold on the PN study but not the CM study is due to the distinct patient populations and the FDA's view of the safety profile in each study.

Financial Projections and Valuation

With a cash balance of $605.1 million, expected to be sufficient to fund operations into the second half of 2027, Intellia Therapeutics is well-positioned to drive its pipeline forward. The company's current valuation metrics, including a P/S Ratio of 23.59, indicate a high growth expectation. As analysts estimate a revenue growth of 387.7% next year, the company's potential for long-term success is evident, but investors should be cautious of the risks associated with the clinical trials and regulatory approvals.

3. NewsRoom

Massachusetts Financial Services Co. MA Makes New $318,000 Investment in Intellia Therapeutics, Inc. $NTLA

Apr -19

Source: defenseworld.net

NTLA Stock Rises 20% in 3 Months: Here's What You Should Know

Apr -16

Source: zacks.com

2 Healthcare Stocks to Buy and 1 to Approach With Caution

Apr -15

Source: fool.com

Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution

Apr -12

Source: 247wallst.com

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr -03

Source: globenewswire.com

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?

Mar -08

Source: fool.com

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar -06

Source: globenewswire.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Brokerages

Mar -06

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.60%)

6. Segments

Genome Editing-based Therapies

Expected Growth: 14.6%

Intellia Therapeutics' 14.6% growth in Genome Editing-based Therapies is driven by increasing adoption of CRISPR technology, strong pipeline of novel treatments for genetic diseases, strategic partnerships, and growing demand for precision medicine. Additionally, advancements in gene editing tools, expanding research collaborations, and favorable regulatory environments contribute to the segment's rapid expansion.

7. Detailed Products

CRISPR/Cas9 Gene Editing

A precise and efficient gene editing technology for treating genetic diseases

CRISPR/Cas12a Gene Editing

A novel gene editing technology for treating genetic diseases with high precision and efficiency

In Vivo CRISPR Gene Editing

A gene editing technology for treating genetic diseases directly in the body

Ex Vivo CRISPR Gene Editing

A gene editing technology for treating genetic diseases outside of the body

Gene Regulation Therapies

A technology for regulating gene expression to treat genetic diseases

8. Intellia Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Intellia Therapeutics, Inc. is medium due to the presence of alternative gene editing technologies such as CRISPR-Cas9 and TALEN. However, Intellia's proprietary CRISPR-Cas12a technology provides a unique advantage in terms of precision and efficiency.

Bargaining Power Of Customers

The bargaining power of customers for Intellia Therapeutics, Inc. is low due to the company's focus on developing novel gene editing therapies for rare genetic diseases, which provides a high level of differentiation and limited alternatives for customers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Intellia Therapeutics, Inc. is medium due to the company's reliance on a few key suppliers for raw materials and equipment. However, the company's strong relationships with suppliers and its ability to negotiate favorable terms mitigate this risk.

Threat Of New Entrants

The threat of new entrants for Intellia Therapeutics, Inc. is high due to the growing interest in gene editing technologies and the potential for new companies to enter the market. However, Intellia's strong intellectual property position and expertise in CRISPR-Cas12a technology provide a barrier to entry for new competitors.

Intensity Of Rivalry

The intensity of rivalry for Intellia Therapeutics, Inc. is high due to the competitive landscape of the gene editing industry, with multiple companies vying for market share and intellectual property dominance. However, Intellia's focus on rare genetic diseases and its proprietary technology provide a unique competitive advantage.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	9.90%
Debt Cost	3.95%
Equity Weight	90.10%
Equity Cost	13.15%
WACC	12.24%
Leverage	10.98%

11. Quality Control: Intellia Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 2.1

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

Arrowhead Pharmaceuticals

A-Score: 4.8/10

Value: 6.0

Growth: 8.6

Quality: 3.3

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

Axsome Therapeutics

A-Score: 4.8/10

Value: 6.0

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

TG Therapeutics

A-Score: 4.2/10

Value: 2.0

Growth: 8.1

Quality: 7.7

Yield: 0.0

Momentum: 4.5

Volatility: 3.0

1-Year Total Return ->

Ultragenyx Pharmaceutical

A-Score: 3.3/10

Value: 6.4

Growth: 4.7

Quality: 3.8

Yield: 0.0

Momentum: 1.0

Volatility: 3.7

1-Year Total Return ->

Intellia Therapeutics

A-Score: 3.0/10

Value: 7.3

Growth: 2.8

Quality: 4.6

Yield: 0.0

Momentum: 2.0

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

23.54%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

12.24%

Intellia Therapeutics, Inc. - US45826J1051

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on NTLA

1.c. Company Highlights

Lower Growth

Weak Momentum

Average Yield

Earnings Beats

Revenues Beats

Stable Momentum

Earnings Miss

Revenues Miss

Average Growth

Fairly Valued

Medium Volatility

2. Intellia Therapeutics' Q4 2025 Earnings: A Deeper Dive into the Numbers and Pipeline Progress

Pipeline Progress and Clinical Trials

Commercial Strategy and Market Potential

Regulatory Updates and Risk Mitigation

Financial Projections and Valuation

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.60%)

6. Segments

Genome Editing-based Therapies

Expected Growth: 14.6%

7. Detailed Products

CRISPR/Cas9 Gene Editing

CRISPR/Cas12a Gene Editing

In Vivo CRISPR Gene Editing

Ex Vivo CRISPR Gene Editing

Gene Regulation Therapies

8. Intellia Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Intellia Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

15.31$

Current Price

15.31$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA